Top-down proteomic profiling of human saliva in multiple sclerosis patients

Manconi, Barbara; Liori, Barbara; Cabras, Tiziana; Vincenzoni, Federica; Iavarone, Federica; Lorefice, Lorena; Cocco, Eleonora; Castagnola, Massimo; Messana, Irene; Olianas, Alessandra

doi:10.1016/j.jprot.2018.07.019

Cited by 45 publications

(34 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IgA represents the main immune barrier against antigens in the mucous membranes and represents the predominant immunoglobulin in secretions such as saliva. Therefore, it was thought to research IgA in the saliva of patients with MS in order to evaluate if it could be used as a potential salivary marker for the diagnosis of MS [78,79].…”

Section: Salivary Biomarkers In Multiple Sclerosismentioning

confidence: 99%

Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases

et al. 2020

View full text Add to dashboard Cite

Many neurological diseases are characterized by progressive neuronal degeneration. Early diagnosis and new markers are necessary for prompt therapeutic intervention. Several studies have aimed to identify biomarkers in different biological liquids. Furthermore, it is being considered whether saliva could be a potential biological sample for the investigation of neurodegenerative diseases. This work aims to provide an overview of the literature concerning biomarkers identified in saliva for the diagnosis of neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Specifically, the studies have revealed that is possible to quantify beta-amyloid1–42 and TAU protein from the saliva of AD patients. Instead, alpha-synuclein and protein deglycase (DJ-1) have been identified as new potential salivary biomarkers for the diagnosis of PD. Nevertheless, future studies will be needed to validate these salivary biomarkers in the diagnosis of neurological diseases.

show abstract

Section: Salivary Biomarkers In Multiple Sclerosismentioning

confidence: 99%

Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…With advances in technology, in addition to the traditional family history portion of a patient's medical record, further characterization of a patient's predisposition to disease can be evaluated by genomic sequencing. For example, recent studies have identified over 200 genomic and proteomic anomalies prevalent in the MS patient population, all directly or indirectly linked to the immune system (International Multiple Sclerosis Genetics Consortium et al, 2013;Manconi et al, 2018; International Multiple Sclerosis Genetics Consortium, 2019; Kotelnikova et al, 2019). Clinical presentation of the disease as well as chronic neuropathology highlight the destructive nature of the interaction between the immune system and the CNS.…”

Section: Introductionmentioning

confidence: 99%

Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis

Titus

Chen

Podojil

et al. 2020

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Multiple Sclerosis (MS) is an immune-mediated neurological disorder, characterized by central nervous system (CNS) inflammation, oligodendrocyte loss, demyelination, and axonal degeneration. Although autoimmunity, inflammatory demyelination and neurodegeneration underlie MS, the initiating event has yet to be clarified. Effective disease modifying therapies need to both regulate the immune system and promote restoration of neuronal function, including remyelination. The challenge in developing an effective long-lived therapy for MS requires that three disease-associated targets be addressed: (1) self-tolerance must be re-established to specifically inhibit the underlying myelin-directed autoimmune pathogenic mechanisms; (2) neurons must be protected from inflammatory injury and degeneration; (3) myelin repair must be engendered by stimulating oligodendrocyte progenitors to remyelinate CNS neuronal axons. The combined use of chronic and relapsing remitting experimental autoimmune encephalomyelitis (C-EAE, R-EAE) ("outside-in") as well as progressive diphtheria toxin A chain (DTA) and cuprizone autoimmune encephalitis (CAE) ("inside-out") mouse models allow for the investigation and specific targeting of all three of these MSassociated disease parameters. The "outside-in" EAE models initiated by myelin-specific autoreactive CD4 + T cells allow for the evaluation of both myelin-specific tolerance in the absence or presence of neuroprotective and/or remyelinating agents. The "inside-out" mouse models of secondary inflammatory demyelination are triggered by toxin-induced oligodendrocyte loss or subtle myelin damage, which allows evaluation of novel therapeutics that could promote remyelination and neuroprotection in the CNS. Overall, utilizing these complementary pre-clinical MS models will open new avenues for developing therapeutic interventions, tackling MS from the "outside-in" and/or "inside-out".

show abstract

“…Salivary samples are non-invasive and more accessible than other body fluids making them a better choice for the development of biomarkers of adverse pregnancy outcomes. Several studies have described the use of saliva as a diagnostic tool for many diseases [46][47][48][49][50] , but the application of saliva in pregnancy study needs further research.…”

Section: Discussionmentioning

confidence: 99%

Salivary proteome signatures in the early and middle stages of human pregnancy with term birth outcome

Dey

Kumar

Singh

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Study Group* the establishment and maintenance of pregnancy in humans proceed through a continuous change of biochemical and biophysical processes. It requires a constant interaction between the fetus and the maternal system. The present prospective study aims to elucidate changes in salivary proteome from the early to middle stages of term pregnancy, and establishing an expressional trajectory for modulated proteins. To date, a comprehensive characterization of the longitudinal salivary proteome in pregnancy has not been performed and it is our immediate interest. In the discovery phase, maternal saliva (n = 20) at 6-13, 18-21, and 26-29 weeks of gestation was analyzed using level-free proteomics (SWATH-MS) approach. The expression levels of 65 proteins were found to change significantly with gestational age and distributed into two distinct clusters with a unique expression trajectory. The results revealed that altered proteins are involved in maternal immune modulation, metabolism, and host defense mechanism. Further, verification of 12 proteins was employed using targeted mass spectrometry (MRM-MS) in a separate subset of saliva (N = 14). The MRM results of 12 selected proteins confirmed a similar expression pattern as in SWATH-MS analysis. Overall, the results not only demonstrate the longitudinal maternal saliva proteome for the first time but also set the groundwork for comparative analysis between term birth and adverse pregnancy outcomes.

show abstract

Top-down proteomic profiling of human saliva in multiple sclerosis patients

Cited by 45 publications

References 81 publications

Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases

Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases

Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis

Salivary proteome signatures in the early and middle stages of human pregnancy with term birth outcome

Contact Info

Product

Resources

About